Brentuximab Vedotin News and Research

RSS
New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Targeted drug doubles progression free survival in Hodgkin lymphoma

Targeted drug doubles progression free survival in Hodgkin lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Novel treatments show promising results in patients with different hematologic disorders

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers